Atrial fibrillation (AF) displays high prevalence in heart failure with preserved ejection fraction (HF-PEF) and compromises prognosis of affected patients. This study aims to assess catheter ablation (CA) for AF in patients with HF-PEF compared to AF-patients without systolic or diastolic dysfunction. Primary endpoints are freedom from AF and quality of life at 1 year. Furthermore, the study is designed to elucidate mechanistic characteristics distinguishing arrhythmic substrate and predicting AF-recurrence in patients with HF-PEF. For this purpose, left atrial concentrations of biomarkers for inflammation, fibrosis and neurohumoral activation are determined and hemodynamic measurements are performed periprocedurally. Information on benefit from CA in these patients is necessary for clinical decision making and mechanistic investigations may point to tailored approaches in order to increase therapeutic efficiency.
Study Type
OBSERVATIONAL
Enrollment
102
Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
University Hospital Heidelberg, Department of Cardiology
Heidelberg, Germany
Arrhythmia recurrence
Clinical arrhythmia and holter-recording
Time frame: 12 months
nTproBNP
\[ng/L\]
Time frame: 12 months
Troponin T
\[pg/mL\]
Time frame: 12 months
Systolic left ventricular function in echocardiography
LVEF \[%\]
Time frame: 12 months
Diastolic left ventricular function in echocardiography
E/e'
Time frame: 12 months
PA-pressure in echocardiography
\[mmHg\]
Time frame: 12 months
Quality of life questionnaire
SF-36
Time frame: 12 months
Diastolic function in stressechocardiography
E/e'
Time frame: 12 months
6-minute-walk-test
\[m\]
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.